Navigation Links
VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
Date:9/9/2008

the New York Times website (http://consults.blogs.nytimes.com). He is also the co-founder of a non-profit organization called The International Partnership for Critical Markers of Disease to promote the development, evaluation, and appropriate clinical utilization of biomarkers. Dr. Libby earned his medical degree at the University of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now Brigham and Women's Hospital).

Webcast Information

A live audiovisual webcast of the presentation can be accessed from the investor section of the VIA website, http://www.viapharmaceuticals.com beginning at 12:00pm EDT on Tuesday, September 16. The webcast will be archived for at least 14 days following the presentation.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple

Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activit
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 China Cord Blood ... China,s leading provider of cord blood collection, ... storage services, today announced that the Company has filed ... Securities and Exchange Commission. The filed Form 20-F includes ... 31, 2015. The Form 20-F can be accessed by ...
(Date:7/30/2015)... 2015 AACC welcomed thousands of medical ... Annual Meeting & Clinical Lab Expo in ... meeting showcased revolutionary advancements in clinical testing technology ... providers to diagnose patients quickly and accurately and ... As of Wednesday, July 29, more ...
(Date:7/30/2015)... ... 2015 , ... The 2015 Market Research Report on the Global Propanol ... global Propanol market with a focus on the Chinese situation. Major companies included in ... ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The ...
(Date:7/30/2015)... July 30, 2015   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... announced that its strategic partner VetStem Biopharma, Inc. ... study of AT-016, an adipose-derived allogeneic stem cell ... of osteoarthritis pain in dogs. The ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... Escalon Extends Product Portoflio with Third FDA Market Clearance Since ... ... 29 Escalon Medical Corp.,(Nasdaq: ESMC ) today announced that ... (FDA) to market the VascuView(TM),Visual Ultrasound System for use with assisted ...
... Jan. 29 Edwards Lifesciences,Corporation (NYSE: EW ), ... cardiovascular disease, plans to announce its operating,results for the ... on,Tuesday, February 5, 2008 and will host a conference ... results., To participate in the conference call, dial ...
... Private Placement of Convertible Preferred Stock -, ... Board: ACCP) announced today that it has executed ... has entered into agreements,with institutional and accredited investors ... proceeds of the Company,s Series A Convertible,Preferred Stock. ...
Cached Biology Technology:Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access 2Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access 3Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access 4Edwards Lifesciences to Host Earnings Conference Call on February 5, 2008 2Access Pharmaceuticals Announces $2.7 Million New Equity 2Access Pharmaceuticals Announces $2.7 Million New Equity 3
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new ... fully hardware encapsulated fingerprint sensor and matching ... is literally off the grid, isolating fingerprint ... within the fingerprint sensor to provide ultimate ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... today announced BD & Guidepoint Mentor, ... free access to Guidepoint,s expert network services. ... developing cutting-edge technologies to improve healthcare delivery and outcomes ... manager, each start-up entrepreneur will be able to directly ...
(Date:7/8/2015)... SPRINGS, Florida , July 8, 2015 ... constantly evolving as this summer,s must have products such as ... in demand as popularity for biometrics based devices continues to ... are NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: ... Inc. (NYSE: FIT ), GoPro, Inc. (NASDAQ: GPRO ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
... detection and destruction by the immune system. Stimulation of the ... are many factors that cause the immune system to ignore ... to suppress the immune system response. In this issue of ... Ronald Levy at Stanford University found that regulatory T cells ...
... Science Automated conserved noncoding sequence ... among grasses Within the genome of each species, ... change in position and sequence over millions of years, but ... stable sequences, so-called conserved noncoding sequences (CNSs), are known to ...
... mechanism by which estrogen suppresses lipid synthesis in the liver, ... treating certain liver diseases. With this finding, Dr. ... in the field. Study results appear in the May 21 ... dogma in the steroid receptor field for 50 years has ...
Cached Biology News:Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
Rabbit polyclonal to JNK1 (phospho T183 + Y185) ( Abpromise for all tested applications). entrezGeneID: 5599 SwissProtID: P45983...
... Abpromise for all tested applications). ... to KLH derived from within residues 400 ... acid sequence is proprietary)(Peptide available as ... ID: 55693 Swiss ...
Rabbit polyclonal to JAK1 (phospho Y1022 + Y1023) ( Abpromise for all tested applications). entrezGeneID: 3716 SwissProtID: P23458...
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
Biology Products: